Roth Capital Sticks to Its Buy Rating for Aimmune Therapeutics (AIMT)

By Ryan Adsit

In a report released today, Jotin Marango from Roth Capital maintained a Buy rating on Aimmune Therapeutics (AIMTResearch Report), with a price target of $80. The company’s shares closed yesterday at $24.09.

Marango observed:

“We expect to hear whether the AR101 BLA will be accepted for filing by the FDA at the end of March, and whether it will receive expedited review in line with its Breakthrough status despite its PDUFA-exempt status. Importantly, we highlight that the clinical efficacy and commercial value proposition of AR101 have not changed, and despite any potential volatility in shares in the next few months (see scenarios below), we expect AR101 to be commercial in 2020. Scenario A. The BLA is accepted, but the FDA gives no indication of expedited review due to Breakthrough status. The BLA is then reviewed through 2019 and approved around January 2020, in line with a 12-month review window typical of PDUFA-exempt filings. At this time, we consider this the base scenario, and assign it a 50% probability. We would expect AIMT shares to trade flat in the short term under this scenario.”

According to TipRanks.com, Marango is ranked 0 out of 5 stars with an average return of -10.4% and a 34.2% success rate. Marango covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Stemline Therapeutics Inc, and Actinium Pharmaceuticals.

Currently, the analyst consensus on Aimmune Therapeutics is a Strong Buy with an average price target of $55.63, implying a 130.9% upside from current levels. In a report issued on February 14, Robert W. Baird also reiterated a Buy rating on the stock with a $64 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $37.81 and a one-year low of $21.22. Currently, Aimmune Therapeutics has an average volume of 705K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.